MaxCyte
Latest round
- Series E
Last raised
- Dec 2014
Total raised
- $29M
Investors
- 7
About MaxCyte
Founded in 1998 and based in Maryland, US, MaxCyte, Inc. is a clinical-stage cell therapeutics company with a pipeline of product development partnerships in cell-based therapies. The company was founded by CEO and President Mr. Doug Doerfler. In 2000, the company developed the MaxCyte GT® Scalable Transfection System for cell therapy development and commercialization. In 2003, the company began entering license agreements with developers of human cell therapies to enable the development of novel therapeutic products based on our delivery platform. In April 2019, MaxCyte launched the ExPERT™ technology platform. In March 2016, MaxCyte was listed at London AIM under the symbol MXCT. MaxCyte is registered on NASDAQ under the ticker symbol MXCT. As of March 2021, the company has 65 full-time employees. The company conducts the discovery and development, manufacturing, and commercialization of cell-based medicines. The product line of the company includes platforms such as ATx, STx and GTx that represent the Flow Electroporation® technology for complex cellular engineering. This technology enables the company's biopharmaceutical partners to advance the development of innovative medicines particularly in cell therapy. The company's cell-engineering platform harnesses the power of the cell to accelerate the development of small molecule drugs, biologics, vaccines, and cell and gene therapies to address a wide array of acute and chronic disease indications. The company's cell-loading technologies use blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company works to develop immune system therapies in a variety of fields, including oncology and cardiology.17 million.
Who invested in MaxCyte
7 investors across 8 rounds
See all investors in MaxCyte
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
Dec 16, 2014
Amount
$1.7M
Investors
Series D
Aug 13, 2009
Amount
$1.1M
Investors
Series D
Aug 13, 2009
Amount
$0.4M
Investors
Series C
Aug 14, 2008
Amount
$2.1M
Investors
Series B
Oct 19, 2007
Amount
$1.2M
Investors
Series B
Nov 23, 2006
Amount
$6.7M
Investors
Series B
Apr 3, 2006
Amount
$5.2M
Investors
Series B
Mar 24, 2004
Amount
$11M
Investors
Questions about MaxCyte
Who invested in MaxCyte?
MaxCyte has 7 investors on record across 8 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MaxCyte raised?
MaxCyte has raised 8 venture rounds. Sign up free to see how much each round raised and the total.
When did MaxCyte last raise money?
MaxCyte's most recent round on record is a Series E, in Dec 2014.
What does MaxCyte do?
Founded in 1998 and based in Maryland, US, MaxCyte, Inc.
Where is MaxCyte headquartered?
MaxCyte is headquartered in Gaithersburg, US.
Which VCs invest in companies like MaxCyte?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at MaxCyte's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like MaxCyte? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.